Floatz logo

gz17-6.02

Castration-resistant Prostate Cancer

Virginia Commonwealth UniversityPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

30 Active assets in the Castration-resistant Prostate Cancer cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 4BBB
RADIUM RA-223
Bayer
Phase 4BB
Abiraterone Acetate
AstraZeneca
Phase 4BB
Zoladex
Bayer
Phase 3BB
Seviteronel
Innocrin Pharmaceutical
Phase 2BB

View all 50 →

Same molecule, other indications

gz17-6.02 is also rated in:

colorectal cancerDormant
CC
Indicative ·
43 / 100
View asset →
Cancer of StomachDormant
CC
Indicative ·
43 / 100
View asset →
gastric adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →